AR and polycystic ovary syndrome: 11-hydroxy and 11-ketoandrogens have been shown to activate the androgen receptor to a greater extent as opposed to classical androgens (Pretorius et al., 2016) and to be associated to a number of pathological conditions such as the polycystic ovary syndrome (O'Reilly et al., 2017; Turcu et al., 2020).